Home / Guides / Tirzepatide plateau
Weight stalled? Here’s what’s normal.
Tirzepatide plateau or not working? What’s normal and what helps
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
A tirzepatide plateau is normal months in, not in your first 4 weeks: Zepbound’s label, read November 1, 2026, calls 2.5 mg a starting dose. If you stall sooner, your provider may check your dose, any missed doses and how your vial is stored and measured.
- Weeks 1 to 4? 2.5 mg is a starting dose
- Months in? Leveling off is normal; tell your provider
- Weight going up? Check missed doses and your vial first
$139/mo on a 12-month plan, all-inclusive, same price at every dose
Or $169/mo month to month
Dose going up? Your price stays the same at every dose
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Lowest monthly price | $139 | $1,668 |
| 6-month | $149 | $1,788 |
| 3-month | $159 | $1,908 |
| Month to month | $169 | $2,028 |
Month to month costs $360 more over 12 months than the 12-month plan. Plans renew until you cancel. Longer plans bill the way you choose at checkout.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviewsLegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
At a glance
Plateau, in brief
The short answers. Each one is explained below.
| Question | Answer |
|---|---|
| When do plateaus happen? | Usually months in. In a 2025 analysis of Zepbound’s SURMOUNT-1 trial, the typical person leveled off 24 to 36 weeks in. |
| Slow loss in weeks 1 to 4? | Not a plateau yet. 2.5 mg is a starting dose; the label’s next step is 5 mg after 4 weeks. |
| What counts as a plateau? | Less than 5% weight change over 12 weeks, and in every 12 weeks after, as the trial analysis measured it. |
| What can you check today? | Missed doses, a vial that got warm or is past its date, and a new vial strength. |
| Who changes your dose? | Only your provider: up in 2.5 mg steps, at least 4 weeks apart, to 15 mg at most. |
| Does a higher dose cost more at NexLife? | No: $139 a month on the 12-month plan, or $169 month to month, at every dose. |
The trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied, and it isn’t FDA-approved. NexLife’s prices checked November 1, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- A tirzepatide plateau usually comes months in: 24 to 36 weeks, typically, in a 2025 analysis of Zepbound’s SURMOUNT-1 trial.
- Most level off by week 72 (about 9 in 10 in that analysis). Compounded tirzepatide wasn’t studied.
- Early on, it isn’t a plateau. Weeks 1 to 4 are on 2.5 mg, a starting dose, not one to stay on.
- Check what you can today: missed doses, a vial that got warm or is past its date, and a new vial strength.
- Only your provider changes your dose: up in 2.5 mg steps, at least 4 weeks apart, to 15 mg at most.
- At NexLife, a higher dose costs the same: $139 a month on the 12-month plan, or $169 month to month.
Plateau or not?
Is it a plateau, or is tirzepatide not working?
Timing tells you most. In a 2025 analysis of SURMOUNT-1, a trial of FDA-approved Zepbound, a plateau meant less than 5% weight change over 12 weeks, and in every 12 weeks after; compounded tirzepatide wasn’t studied. At 200 pounds, 5% is 10 pounds. In your first weeks on 2.5 mg, slow change isn’t a plateau yet.
| What you’re seeing | What it may mean | What to do |
|---|---|---|
| Slow change in the first weekson 2.5 mg | Not a plateau yet. The label calls 2.5 mg a dose for starting treatment, not one to stay on. | Keep to your schedule. The label’s next step is 5 mg after 4 weeks; your provider decides. |
| Losing, but more slowlymonths in | Expected. Loss slows over time, then levels off. | Keep going as prescribed, and watch your weight over 12 weeks, the span the trial analysis used. |
| Under 5% change in 12 weeksafter months of loss | Likely a plateau, as the trial analysis measured it. The typical person reached one 24 to 36 weeks in. | Tell your provider. They may keep your dose or step it up. |
| Weight going back up | Not a plateau. Look at missed doses, a break and your vial. | Tell your provider, and run the vial checks below. |
| Little or no loss after monthsat 5 mg or more | A smaller response. In SURMOUNT-1, 9 in 10 people on 15 mg lost at least 5%, so not everyone did. | Your provider reviews your dose, your vial and your other options. |
Swipe the table sideways to see every column.
From the Zepbound prescribing information (revised August 2026) and Horn et al., Clinical Obesity, 2025. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Trial data
When do tirzepatide plateaus happen?
Usually months in. In a 2025 analysis of SURMOUNT-1, the typical person leveled off 24 to 36 weeks in, depending on starting BMI. That’s among people who kept taking it and lost at least 5%. The trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied. Stalled sooner? Start with your dose and your vial.
Weeks from the start of the 72-week trial, among 1,438 people who kept taking tirzepatide and lost at least 5%. A plateau meant less than 5% weight change over 12 weeks, and in every 12 weeks after. The smaller figure is the share who had plateaued by week 72. BMI classes as the CDC defines them. Horn et al., Clinical Obesity, 2025. The trial studied Lilly’s tirzepatide, sold as FDA-approved Zepbound (and as Mounjaro for type 2 diabetes); compounded tirzepatide wasn’t studied.
- A higher starting BMI meant more time losing. People with class 2 or 3 obesity leveled off at 36.1 weeks, versus 24.3 weeks for people who started overweight.
- Dose, age and sex mattered too. People on higher doses, younger people and women tended to plateau later. The analysis’s second trial, SURMOUNT-4, showed similar results.
- Stalled at 3 months? That’s earlier than for most people here: in every BMI group, the typical person leveled off at 24 weeks or later. The 8 reasons below are worth a look.
- By week 72, about 9 in 10 had leveled off in every BMI group (87.6% to 90.2%).
“In this post-hoc analysis, most participants reached a weight plateau by week 72.”
8 reasons
Why does weight loss stall on tirzepatide? 8 reasons
Some are part of how tirzepatide works: loss slows, then levels off. And the Zepbound label (revised August 2026) treats the first 4 weeks at 2.5 mg as a starting dose. Others you can check today, such as missed doses, a warm vial or a new vial strength. Rule those out before anyone changes your dose.
“The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
You’re still on a starting dose
The Zepbound label starts everyone at 2.5 mg a week for 4 weeks, a dose for starting treatment, not one to stay on. After that, doses rise in 2.5 mg steps, at least 4 weeks apart, up to 15 mg.
You’ve reached a plateau
Weight loss slows over time, then levels off. In the SURMOUNT-1 analysis, about 9 in 10 people who kept taking tirzepatide and lost at least 5% had leveled off by week 72.
Your starting BMI, age and sex
People who started overweight leveled off sooner than people with class 2 or 3 obesity. Older people and men tended to plateau sooner, too. These are patterns in a group, not a forecast for you.
Your dose
People on higher doses tended to keep losing longer before they leveled off. Whether a step up fits you is your provider’s call.
Type 2 diabetes
In Zepbound’s trials, people with type 2 diabetes lost less weight on average than people without it.
Missed doses or a break
The label’s window for a missed dose is 4 days. After a longer gap, your provider may restart you lower, and weight can come back while you’re off it. More on restarting tirzepatide after a break.
Your vial or your units
Don’t use a vial that arrived warm, froze or is past its date. And a new vial strength changes how many units make your dose. The checks are below.
Food and activity
In the trials, tirzepatide was paired with a reduced-calorie diet and more physical activity. A 2025 joint advisory from four obesity and nutrition groups lists adequate protein and strength training among its priorities, to preserve lean mass. More: what to eat on a
GLP-1 .
Reasons 2 to 4 come from Horn et al., Clinical Obesity, 2025; the label facts come from the Zepbound prescribing information. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Step by step
How do you handle a tirzepatide plateau?
Check what you can, then talk to your provider. Five steps, in order.
- Check the timing. In weeks 1 to 4 on 2.5 mg, slow change isn’t a plateau yet: that’s a starting dose.
- Watch 12 weeks. The trial analysis called it a plateau when weight changed by less than 5% over 12 weeks, and in every 12 weeks after.
- Rule out missed doses. The label’s window for a missed dose is 4 days. After a longer gap, your provider may restart you lower.
- Check your vial. Its strength sets your units. Don’t use a vial that arrived warm, froze or is past its date.
- Talk to your provider. Only your provider changes your dose: a step up, the same dose, a lower dose or a different medicine.
Your provider
What can your provider change if you plateau?
Only your provider changes your dose, and there are four options: a step up, the same dose, a lower dose or a different medicine. The Zepbound label (revised August 2026) allows steps of 2.5 mg, at least 4 weeks apart, up to 15 mg a week. Bring your dose, your weight trend and any side effects to that talk.
“The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
A step up
The label allows a 2.5 mg step after at least 4 weeks on your current dose, up to 15 mg a week.
The same dose
If your weight has leveled off where you and your provider want it, staying put is maintenance. The label’s maintenance doses are 5, 10 and 15 mg. More on the tirzepatide maintenance dose.
A lower dose
If side effects are what’s holding you back, the label says to consider a lower maintenance dose.
A different medicine
For some people, that’s semaglutide. It’s a new prescription, and the labels say not to take the two together. More below.
Don’t change your dose yourself. The FDA has reports of side effects that may be linked to compounded tirzepatide at doses higher than the approved label allows, or raised faster than its steps. Took too much by mistake? Call 911 for an emergency; otherwise call Poison Control at 1-800-222-1222, then your prescriber.
Your vial
Could your vial be the problem?
Sometimes, and it takes a minute to check. Three things can change your dose or the medicine: the strength on the label, how the vial was stored and its dates. The FDA’s
“Discard the vial within 28 days after the first use, even if medication remains in the vial.”
U.S. Food and Drug Administration, FDA’s Concerns with UnapprovedGLP-1 Drugs Used for Weight Loss
The strength on your label
It’s in mg per mL, and it sets your units. The same 50 units is 5 mg from a 10 mg/mL vial and 10 mg from a 20 mg/mL vial. New vial, new strength? Recheck the math with our tirzepatide dosage chart.
The storage
Most compounded vials go in the fridge at 36°F to 46°F, never frozen, but your label sets the rule. Don’t use a vial that arrived warm or froze. Traveling? See flying with tirzepatide.
The dates
Use an opened vial within 28 days, or by the beyond-use date on its label if that comes first, even if some is left.
50 units on a U-100 syringe is 0.5 mL. How much medicine that holds depends on the vial’s strength, so give your provider the milligrams on your label, not the units.
| Dose | At 10 mg/mL (example) | At 20 mg/mL (example) |
|---|---|---|
| 2.5 mg | 0.25 mL = 25 units | 0.125 mL = 12.5 units |
| 5 mg | 0.5 mL = 50 units | 0.25 mL = 25 units |
| 7.5 mg | 0.75 mL = 75 units | 0.375 mL = 37.5 units |
| 10 mg | 1 mL = 100 units | 0.5 mL = 50 units |
| 12.5 mg | 1.25 mL, more than a 1 mL syringe holds | 0.625 mL = 62.5 units |
| 15 mg | 1.5 mL, more than a 1 mL syringe holds | 0.75 mL = 75 units |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. Double the strength and the same dose takes half the units. 10 and 20 mg/mL are examples only: your vial’s label decides the strength, and your prescription sets your dose.
A stall alone doesn’t prove a weaker vial. Most people in Zepbound’s trial leveled off too, and that trial didn’t study compounded tirzepatide. More on compounded tirzepatide storage.
Something looks off? NexLife members can call or text
Cost
Does a higher dose cost more?
It depends on how your program sets prices. At LillyDirect, Zepbound is $399 at 5 mg and $449 from 7.5 mg to 15 mg, per 28 days, with a refill within 45 days ($499 at 7.5 mg and $699 at 10 to 15 mg otherwise; checked November 1, 2026). Where the price follows the dose, a step up raises your bill. With one price at every dose, it costs nothing more.
| Program | At a lower dose | At a higher dose | What a step up adds |
|---|---|---|---|
| Zepbound at LillyDirectbrand-name; per 28 days | $299 at 2.5 mg; $399 at 5 mg | $449 from 7.5 mg to 15 mg | +$100, then +$50 |
| Shapelycompounded; with its $99 monthly membership | $348 at low to mid doses | $398 at high doses | +$50 a month |
| Mochi Healthcompounded; with its $79 monthly membership | $169 a month at its lowest dose | Priced by dose | More as the dose rises |
| NexLife (ours)compounded; one price at every dose | $139 a month on the 12-month plan; $169 month to month | The same: $139 on 12 months; $169 month to month | $0 |
Swipe the table sideways to see every column.
Monthly price, all in, from each company’s own site, checked November 1, 2026. LillyDirect’s $449 needs a refill within 45 days of the last one; otherwise it’s $499 at 7.5 mg and $699 at 10 to 15 mg. Compounded tirzepatide isn’t FDA-approved; Zepbound is.
One price at every dose isn’t rare. Nine of the 14 compounded programs in our
Priced by dose can cost less while your dose is low. Compare the price at the dose you expect to reach, not just the one you’re on. Every program, dose by dose: tirzepatide price by dose.
At NexLife, your dose never changes your price: $139 a month on the 12-month plan, or $169 month to month, from 2.5 mg to 15 mg, with no membership fee.
Semaglutide
Not working on tirzepatide, but semaglutide worked?
It can happen, and it may be early days. The Zepbound label (revised August 2026) starts everyone at 2.5 mg, so you may still be stepping up. Tell your provider what worked before: your semaglutide dose, how long you took it and how you felt. Switching back is an option, with a new prescription.
You may still be stepping up
The Zepbound label starts everyone at 2.5 mg, whatever they took before, and there’s no official conversion between the two medicines.
Averages aren’t you
In the head-to-head SURMOUNT-5 trial, average weight loss over 72 weeks was 20.2% on tirzepatide and 13.7% on semaglutide. An average doesn’t predict how you’ll respond.
Switching back is an option
It’s a new prescription, and your provider decides the dose and the timing. The labels say not to take the two together.
SURMOUNT-5 (The New England Journal of Medicine, 2025) studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied. More on switching: semaglutide to tirzepatide.
At NexLife
Stalled? What happens at NexLife
A licensed provider looks at your dose before anything changes, and your price stays the same whatever they decide.
Tell us where you are
Your dose in milligrams, how long you’ve been on it, how your weight has changed, missed doses and side effects. Members: call or text
(949) 818-8000 , 24/7. New to NexLife? Start with a 3-minute online assessment.A licensed provider decides
Whether to keep your dose, step it up or lower it. Your dose follows how you respond, never the price.
Your price stays put
$139 a month on the 12-month plan, or $169 month to month, at every dose from 2.5 mg to 15 mg. No membership fee.
Help between doses
A nutrition plan and a 1:1 coaching call are included. We check with your provider and the pharmacy on dosing questions, so you never have to chase anyone.
Stalled at another program? If you have an active prescription and pay less there for compounded tirzepatide, our Price Match Guarantee† matches your regular monthly price on our month-to-month plan. See the terms.
Prefer semaglutide? Compounded semaglutide is $119 a month on the 12-month plan, or $139 month to month, also the same at every dose.
Two medications.
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Keep your price.
Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Plateaus: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
When does weight loss plateau on tirzepatide?
Usually months in. In a 2025 analysis of Zepbound’s SURMOUNT-1 trial, people who kept taking it and lost at least 5% typically leveled off 24 to 36 weeks in: 24.3 weeks if they started overweight, 36.1 weeks with class 2 or 3 obesity. By week 72, about 9 in 10 had leveled off. Compounded tirzepatide wasn’t studied.
How long does a tirzepatide plateau last?
There’s no set length, and on the same dose it may not end. In the SURMOUNT-1 analysis, a plateau counted only if weight then changed by less than 5% in every 12 weeks that followed, through week 72; compounded tirzepatide wasn’t studied. Your provider can weigh a dose change, or treat your new weight as the one to maintain.
Why did tirzepatide stop working?
It may not have: weight loss on tirzepatide slows, then levels off. In a 2025 SURMOUNT-1 analysis, about 9 in 10 people who kept taking it and lost at least 5% had plateaued by week 72 (compounded tirzepatide wasn’t studied). Rule out missed doses, a warm or out-of-date vial, a new vial strength, or a dose still stepping up.
Should I increase my dose if I plateau?
That’s your provider’s call, so don’t change your dose on your own. The Zepbound label allows 2.5 mg steps, at least 4 weeks apart, up to 15 mg. In a SURMOUNT-1 analysis of FDA-approved Zepbound, people on higher doses tended to plateau later; compounded tirzepatide wasn’t studied. Staying on a dose that holds your new weight is an option too.
Does tirzepatide stop working over time?
Not in the trials, for people who kept taking it: in SURMOUNT-4, those who continued after 36 weeks lost another 5.5% on average over the next 52 weeks, while those switched to placebo regained 14.0%. What slows is the pace of loss, which is what a plateau is. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Tirzepatide isn’t working in my first weeks. Is that normal?
It can be: weeks 1 to 4 are at 2.5 mg, which the Zepbound label calls a dose for starting treatment, not one to stay on. The dose then rises in 2.5 mg steps, at least 4 weeks apart, as your provider decides. Keep to your schedule, and ask your provider if anything worries you.
Is my compounded tirzepatide weaker?
A stall on its own doesn’t show that: most people in Zepbound’s trial leveled off too, and that trial didn’t study compounded tirzepatide. Compounded tirzepatide isn’t FDA-approved, so check what you can: the strength on your label, the beyond-use date and how it was stored. NexLife member? Call or text
Tirzepatide isn’t working, but semaglutide did. Can I switch back?
Yes, if your provider agrees: it’s a new prescription, and the labels say not to take the two together. If you switched recently, you may still be in tirzepatide’s dose steps, which start at 2.5 mg. In SURMOUNT-5, average loss was 20.2% on Zepbound and 13.7% on Wegovy at 72 weeks, but averages don’t predict your response.
Does a higher dose cost more at NexLife?
No. At NexLife, compounded tirzepatide is $139 a month on the 12-month plan, or $169 month to month, at every dose. At LillyDirect, a step up costs more: Zepbound is $399 at 5 mg and $449 from 7.5 mg with a refill within 45 days, or $499 to $699 otherwise (checked November 1, 2026).
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and checked this page
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Plateau analysis re-read November 1, 2026. Label read November 1, 2026; prices checked November 1, 2026.
- How we checked. The plateau timing comes from a 2025 analysis of the SURMOUNT-1 and SURMOUNT-4 trials, published in Clinical Obesity. We re-read its abstract on November 1, 2026 and give its numbers as published. Dose steps and the other trial figures come from the Zepbound prescribing information (revised August 2026), and the vial guidance from the FDA, both read November 1, 2026. Competitor prices are those on our price pages, checked November 1, 2026. We don’t give a dosing plan: your provider decides.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
Stalled? A licensed provider can review your dose.
Start with a 3-minute online check. A licensed provider decides your dose, and the price is the same at every one: $139 a month on the 12-month plan, or $169 month to month.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, or by secure video where your state requires a live visit. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity, 2025. Abstract re-read November 1, 2026.
- Zepbound (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 1, 2026.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. Read October 21, 2026.
- FDA: concerns with unapproved
GLP-1 drugs used for weight loss (updated October 1, 2026). Read November 1, 2026. - FDA: Compounding and the FDA, questions and answers.
- Nutritional priorities to support
GLP-1 therapy for obesity: a joint advisory of four groups (The Obesity Society, May 30, 2025). Read November 1, 2026. - CDC: Adult BMI categories. Read November 1, 2026.
- LillyDirect: Zepbound self-pay prices. Checked November 1, 2026.
- Shapely: compounded tirzepatide prices. Checked November 1, 2026.
- Mochi Health: FAQs (membership and medication prices). Checked November 1, 2026.
- NexLife:
GLP-1 price index (dose pricing for every program). Checked November 1, 2026. - NexLife: pricing, every plan. Checked November 1, 2026.
- NexLife: Price Match Guarantee† terms. Read November 1, 2026.
- Eli Lilly and Company, via Drugs@FDA. ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information, revised 02/2026. Read November 2, 2026.
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. Read November 2, 2026.
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Read November 2, 2026.